Neogenomics (NEO) Gross Profit (2010 - 2026)

Neogenomics has reported Gross Profit for 17 years, with the latest figure at $80.9 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 10.4% year-over-year to $80.9 million; the trailing twelve-month figure through Mar 2026 stood at $321.9 million (up 8.07% YoY), and the FY2025 full-year result was $314.3 million, up 8.34% from the prior year.
• Gross Profit for Q1 2026 stood at $80.9 million, down from $83.3 million in the prior quarter.
• The five-year high for Gross Profit was $83.3 million in Q4 2025, with the low at $38.2 million in Q1 2022.
• Historically, Gross Profit has averaged $65.8 million across 5 years, with a median of $67.6 million in 2023.
• Annual changes were most pronounced in 2022 — Gross Profit fell 17.07% — and 2023, when it surged 43.37%.
• Neogenomics' Gross Profit stood at $56.8 million in 2022, then rose by 18.94% to $67.6 million in 2023, then gained by 14.31% to $77.3 million in 2024, then advanced by 7.88% to $83.3 million in 2025, then retreated by 2.97% to $80.9 million in 2026.
• The last three Gross Profit figures came in at $80.9 million (Q1 2026), $83.3 million (Q4 2025), and $80.4 million (Q3 2025), per Business Quant data.